Race Oncology Ltd.
(ASX: RAC)

Race Oncology Ltd. is a clinical stage biotechnology company, which engages in the discovery and development of a novel approach to cancer treatment and cardio protection. The firm is involved in developing Bisantrene, a small molecule anthracene chemotherapeutic, to address the unmet need of patients across multiple oncology indications, with an initial focus on metastatic breast cancer and acute myeloid leukemia. It is also investigating the impact Bisantrene and new molecules have on the m6A RNA pathway. The company was founded on February 15, 2011 and is headquartered in Sydney, Australia.

1.335

-0.055 (-3.96%)
Range 1.335 - 1.395   (4.49%)
Open 1.395
Previous Close 1.390
Bid Price -
Bid Volume -
Ask Price -
Ask Volume -
Volume 10,571
Value -
Remark
End-of-day (EOD) prices. Updated for 29 May 2025.
Data powered by
View All Events

Share your investing ideas
Please login to view stock data and analysis